Dividend
-
-
-
-
-
-
-
Merrimack Pharma (MACK) Declares Approximately $0.50 Special Dividend; Approximately 13.3% Yield
-
-
-
-
-
-
-
Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend
-
-
-
-
-
-
-
Merrimack Reports Second Quarter 2017 Financial Results
-
-
-
-
-
-
-
Merrimack Pharma (MACK) Launches New R&D Entity with Ipsen SA (IPSEY) Following Completion of $1B ONIVYDE® Deal
-
-
-
-
-
-
-
Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO
-
-
-
-
-
378,383 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All